ABUS - Arbutus Biopharma GAAP EPS of -$0.12 misses by $0.01 revenue of $4.66M misses by $0.06M reduces 24% workforce
2023-11-07 07:36:28 ET
More on Arbutus Biopharma
- Putting Arbutus Biopharma Back In The Spotlight
- Arbutus Biopharma Corporation 2023 Q2 - Results - Earnings Call Presentation
- Alnylam sends Arbutus lower after FDA snub for amyloidosis drug
- Arbutus ends development of COVID, hepatitis b candidates
- Seeking Alpha’s Quant Rating on Arbutus Biopharma
For further details see:
Arbutus Biopharma GAAP EPS of -$0.12 misses by $0.01, revenue of $4.66M misses by $0.06M, reduces 24% workforce